Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2004-08-27
2008-12-09
Henley, III, Raymond J (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S400000, C514S649000
Reexamination Certificate
active
07462618
ABSTRACT:
The present invention discloses a novel compound and method for the treatment of inflammatory autoimmune diseases, for example, rheumatoid arthritis, using α-adrenergic antagonists and β-adrenergic agonists in combination. Treatment of animals, namely humans, with an α-adrenergic antagonist, preferably, phentolamine, and a β-adrenergic agonist, preferably terbutaline, in combination can significantly suppress the joint destruction and inflammation due to disease in these animals.
REFERENCES:
patent: 5264459 (1993-11-01), Chelmicka-Schorr et al.
patent: 5513661 (1996-05-01), Hubbard
patent: 6610905 (2003-08-01), Lira et al.
patent: 6613958 (2003-09-01), Neuhold et al.
patent: WO 9221981 (1992-12-01), None
Lubahn et al., “Chronic Treatment with Adrenergic Agents Attenuates the Inflammation and Bone Destruction associated with Adjuvant Arthritis (AA)”, Society for Neuroscience Abstracts, (2001), (Biosis Abstract; 2001).
Abrass, C., et al.: Characterization of the beta-adrenergic receptor of the rat peritoneal macrophage.J Immunol135:1338-1341(1985).
Ackerman, N., et al.: Effects of naproxen on connective tissue changes in the adjuvant arthritic rat.Arthritis Rheum22:1365-1374 (1979).
Aguilera, G., et al.: Differential regulation of hypothalamic pituitary corticotropin releasing hormone receptors during development of adjuvant-induced arthritis in the rat.J Endocrinol153:185-91 (1997).
Albalas, J., et al.: Gi-mediated activation of the p21ras-mitogen-activated protein kinase pathway by α2-adrenergic receptors expressed in fibroblasts.J Biol Chem268:22235-22238 (1993).
Allen, J., et al.: Suppression of monocyte function and differential regulation of IL-1 and IL-1ra by IL-4 contribute to resolution of experimental arthritis.J Immunol151 (1993) 4333-4351.
Arai, K., et al.: Cytokines: Coordinators of immune and inflammatory responses.Ann Rev BioChem59:783-836 (1990).
Baerwald, C., et al.: Decreased density of beta-adrenergic receptors on peripheral blood mononuclear cells in patients with rheumatoid arthritis.J Rheumatol19:204-210 (1992).
Baerwald, C., et al.: Impaired sympathetic influence on the immune response in patients with rheumatoid arthritis due to lymphocyte subset-specific modulation of beta 2-adrenergic receptors.Br J Rheumatol36:1262-1269 (1997).
Baghai, M., et al.: Fatal sepsis in a patient with rheumatoid arthritis treated with etanercept.Mayo Clin Proc76:573-575 (2001).
Bartik, M., et al.: Modulation of T cell proliferation by stimulation of the beta-adrenergic receptor: lack of correlation between inhibition of T cell proliferation and cAMP.J Immunol154:408-21 (1993).
Bauman, G., et al.: Induction of cAMP-dependent protein kinase (PKA) activity in T cells after stimulation of the prostaglandin E2or the beta-adrenergic receptors: relationship between PKA activity and inhibition of anti-CD3 monoclonal antibody-induced T cell proliferation.Cell Immunol158:182 (1994).
Bellinger, D., et al.: In R.Ader, D.L.Felten, and N.Cohen (eds.)Psychoneuroimmunology. III, Academic Press, San Diego, pp. 55-111 (2000).
Bellinger, D., et al.: Noradrenergic sympathetic innervation of thymus, spleen, and lymph nodes: Aspects of development, aging and plasticity in neural immune interaction. In JW. Hadden, K. Masek and G. Nistico (Eds.)Interactions Among Central Nervous System, Neuroendocrine and Immune Systems, Pythagora Press, Roma, Milano, pp. 35-66 (1989).
Besedovsky, J, et al.: Immunoregulation mediated by the sympathetic nervous systemCell Immunol48:346-355 (1979).
Betz, M. et al.: Prostaglandin E2inhibits production of Th1 lymphokines but not of Th2 lymphokines.J Immunol146:108-13 (1991).
Binderup, L., et al.: Splenic suppressor cells in adjuvant arthritic rats: effect of D-penicillamine.Agents and Actions7 Suppl. 199-203 (1980).
Brown, S., et al.: Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration.Arthritis Rheum46:3151-3158 (2002).
Burchiel, S., et al.: Augmentation of the in vitro humoral immune response by pharmacologic agents. II: The comparison of the effects of antiproliferative agents with dibutyryl cAMP.Immunopharmacol1:151-163 (1979b).
Burchiel, S., et al.: Augmentation of the in vitro humoral immune response by pharmacologic agents I: An explanation of the differential enhancement of humoral immunity via agents that elevate cAMP.Immunopharmacol1:137-150 (1979a).
Burmester, G., et al.: Differential expression of Ia antigen by rheumatoid synovial lining cells.J Clin Invest80:595-604 (1987).
Burmester, G., et al.: Mononuclear phagocytes and rheumatoid synovitis: mastermind or workhorse in arthritis?Arthritis Rheum40:5-18 (1997).
Camilleri, J., et al.: The effect of free and liposome-encapsulated clodronate on the hepatic mononuclear phagocyte system in the rat.Clin Exp Immunol99:269-275 (1995).
Charles, P., et al.: Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis.J Immunol163:1521-1528 (1999).
Chelmicka-Schorr, E., et al.: The beta 2-adrenergic agonist terbutaline suppresses acute passive transfer experimental autoimmune myasthenia gravis (EAMG),Int J Immunopharmacol15:19-24 (1993).
Chelmicka-Schorr, E., et al.: The beta-adrenergic agonist isoproterenol suppresses experimental allergic encephalomyelitis in Lewis rats.J NeuroImmuno25:203-207 (1989).
Chen, D., et al.: Interleukin 2 transcription factors as molecular targets of cAMP inhibition: delayed inhibition kinetics and combinatorial transcription roles.J Exp Med179:931-42 (1994).
Cook, S., et al.: Inhibition by cAMP of Ras-dependent activation of Raf.Science262:1069-1072 (1993).
Damoiseaux, J., et al.: Expression of the ED3 antigen on rat macrophages in relation to experimental autoimmune diseases.Immunobiology84:311-320 (1992).
Dijkstra, C., et al.: Macrophages and dendritic cells in antigen-induced arthritis: an immunohistochemical study using cryostat sections of the whole knee joint of rat.Scand J Immunol26:513-523 (1987).
Edmonds, J., et al.: Anti-rheumatic drugs: a proposed new classification.Arthritis Rheum36:336-306 (1993).
Elenkov, I., et al.: Modulatory effects of glucocoricoids and catecholamines on human interleukin-12 and interleukin-10 production: clinical implications.Proc Assoc Amer Physic108:374-381 (1996).
Elliott, M., et al.: Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis.Lancet344:1105-1110 (1994).
Feige, U., et al.: Anti-interleukin-1 and anti-tumor necrosis factor-alpha synergistically inhibit adjuvant arthritis in Lewis rats.Cell Mol Life Sci57:1457-1470 (2000).
Feige, U., et al.: Combining anti-IL-1 and anti-TNF treatments provides better efficacy in rat adjuvant arthritis than does either agent alone.Arthritis Rheum452:S383 (1999).
Feldmann, M., et al.: Anti-TNF-alpha therapy of rheumatoid arthritis: What have we learned?Annu Rev Immunol19:163-196 (2001).
Felten, D., et al.: Noradrenergic sympathetic neural interactions with the immune system: structure and function.Immunol Rev100:225-260 (1987).
Fox, D.: The role of T cells in the immunopathogenesis of rheumatoid arthritis.Arthritis Rheum40:598-609 (1997).
Fries, J., et al.: Measurement of patient outcome in arthritis.Arthritis Rheum23:137-145 (1980).
Hart, P., et al.: Regulatory effects of IL-13 on synovial fluid macrophages and blood monocytes from patients with inflammatory arthritis.Clin Exp Immuno99:331-337 (1995).
Haskû, G., et al.: Regulation of cytokine and chemokine production by transmitters and co-transmitters of the autonomic nervous system.Biochem Pharmacol56:1079-1087 (1998).
Hawes, B., et al.: Distinct pathways of Gi- and Gq-mediated mitogen-activated protein kinase activation.J Biol Chem270:17148-17153 (1995).
Heijnen, C., et al.: Functional alpha 1-adrenergic receptors on leukocytes of patients with polyarticular juvenile rheumatoid arthritis.J NeuroImmunol71: 223-226 (1996).
Hemler, M., et al.: Antigenic stimulation regulates th
Lorton Dianne
Lubahn Cheri
Henley, III Raymond J
Jennings Strouss & Salmon
Mott Joseph W.
Sun Health Research Institute
LandOfFree
Treatment of inflammatory autoimmune diseases with... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of inflammatory autoimmune diseases with..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of inflammatory autoimmune diseases with... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4022251